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leles in all analysed samples.  Conclusions: The lack of filag-
grin expression observed in the analysed corneal speci-
mens from AD patients is not due to the two most common 
 FLG mutations (R501X, 2282del4) but is most likely second-
ary to inflammation, as all keratitis specimens of non-AD 
patients showed lack of filaggrin expression as well. 
 © 2013 S. Karger AG, Basel 
 Introduction 
 Filaggrin is expressed in the stratum corneum (SC) of 
healthy skin and is essential for the regulation of epider-
mal homeostasis. Derived from the large, complex, high-
ly phosphorylated precursor profilaggrin, filaggrin 
 monomers interact with keratin intermediate filaments 
to form macrofibrils. In the upper layers of the SC, filag-
grin monomers are further degraded to free amino acids 
 [1] that are important in maintaining the hydration of the 
SC. Up to 10% of the European population are affected by 
filaggrin deficiency due to inheritance of a single  FLG null 
mutation and suffer from dry and scaly skin and are at 
risk of developing atopic dermatitis (AD)  [2–6] . Large-
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 Abstract 
 Background: Filaggrin is expressed in the epidermis and is 
essential for the maintenance of the epidermal barrier. Null 
mutations within the filaggrin gene  (FLG) lead to a dis-
turbed epidermal barrier and are associated with a signifi-
cantly increased risk of atopic dermatitis (AD). The associa-
tion of AD with ocular surface disorders prompted us to 
speculate that common  FLG mutations may be particularly 
prevalent in AD patients with ocular comorbidities.  Meth-
ods: Corneal buttons and biopsies from AD patients with 
ocular involvement (n = 11) and from non-atopic patients 
(n = 9) with a histological diagnosis of keratitis were includ-
ed in the study. DNA samples obtained from paraffin-em-
bedded corneal specimens were genotyped for the two 
most common  FLG mutations (R501X and 2282del4). Filag-
grin protein expression was analysed by immunohisto-
chemistry.  Results: Normal skin and corneal specimens (n = 
6) were positive for filaggrin, which could be detected in the 
stratum corneum of the skin and in the basal epithelial lay-
er of the cornea. Interestingly, all AD corneal specimens as 
well as the specimens from keratitis patients without AD 
were negative for filaggrin expression. Genotyping of the 
 FLG mutations R501X and 2282del4 revealed wild-type al-
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scale meta-analyses showed that up to 25% of all and up 
to 50% of severe AD patients carry one  FLG mutation and 
that these patients, in addition, have a greater risk of mul-
tiple allergies, asthma, rhinitis, and skin infections  [3–6] . 
In Europeans, two recurrent mutations (R501X and 
2282del4) account for 80% of the total risk alleles, while 
there are many low-frequency variants in Asian popula-
tions  [7] .
 Many AD patients suffer from severe chronic ocular 
surface disorders, indicating that AD leads to a complex 
immunological disturbance of the ocular surface, often 
involving the lid margin, the conjunctiva and the cornea. 
These can result in any combination of blepharitis, con-
junctivitis and/or keratitis. Bacterial and viral superinfec-
tions can worsen the clinical course  [8] , resulting in punc-
tate epithelial keratopathy, persistent epithelial defects, 
shield ulcers, and corneal vascularization  [9, 10] . Interest-
ingly, apart from the ocular surface complications, AD is 
also associated with keratoconus  [11] .
 The association of AD with ocular surface disorders 
prompted us to speculate that common  FLG mutations 
may be particularly prevalent in AD patients with ocular 
comorbidities. Therefore, we looked for the most com-
mon  FLG mutations R501X and 2282del4 in corneal 
specimens with AD-associated changes and compared 
the filaggrin expression in those specimens with corneal 
specimens from keratitis patients without AD.
 Material and Methods 
 Patients 
 Corneal buttons (n = 8) and biopsies (n = 3) from AD patients 
with ocular involvement and corneal buttons (n = 9) from non-
atopic patients with a histological diagnosis of keratitis (5 cases of 
acute and 4 cases of chronic keratitis) were included in the study 
( table 1 ). Informed consent was received from all patients, and the 
study was approved by a local Research Ethics Committee. All 
specimens were collected in the Division of Ophthalmopathology 
Table 1.  List of patients involved in this case series
Patient Histological diagnosis Sample Atopic disorders Filaggrin 
IHC
Patients with atopic disorders
1.1 Acute and chronic keratitis CB AD negative 
1.2 Atopic plaque BSY AD (since early childhood) negative
1.3 Corneal ulcer CB AD negative
1.4 Chronic keratitis with epithelial and stromal scars CB AD, AA, FA (peanuts, 
pollen, house dust)
negative
1.5 Chronic keratitis, endothelial decompensation CB AD, AA negative
1.6 Corneal ulcer CB AD negative
1.7 Acute and chronic keratitis CB AD negative
1.8 Acute and chronic keratitis, corneal conjunctivalization BSY AD, AA negative
1.9 Atopic plaque BSY AD, AA negative
1.10 Acute and chronic keratitis CB AD negative
1.11 Corneal amyloidosis, st.p. atopic plaques, keratitis, and corneal ulcer CB AD negative
Keratitis patients without atopic disorders
2.1 Chronic keratitis, st.p. corneal ulcer CB none negative
2.2 Acute keratitis, Pseudomonas infection CB none negative
2.3 Acute keratitis, corneal ulcer, calcifications CB none negative
2.4 Acute keratitis CB none negative
2.5 Chronic keratitis, corneal scar CB none negative
2.6 Acute keratitis, corneal graft failure CB none negative
2.7 Chronic keratitis, corneal graft failure, retrocorneal membrane CB none negative
2.8 Chronic keratitis, st.p. amniotic membrane CB none negative
2.9 Acute keratitis (Lyell’s syndrome), retrocorneal membrane CB none negative
 Corneal samples of 11 patients with a positive history of AD were analysed in terms of filaggrin expression in corneal and conjunc-
tival specimens. As controls, 9 corneal buttons from keratitis patients without any history of atopic disorders were used. The diagnosis 
of AD was based on the criteria of Hanifin and Rajka [12]. CB = Corneal button; BSY = biopsy; AA = allergic asthma; FA = food allergy; 
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of the University Eye Hospital Freiburg, Freiburg im Breisgau, 
Germany. The diagnosis of AD was based on the criteria of Hani-
fin and Rajka  [12] ; the ophthalmological diagnosis according to 
the patients’ files was confirmed histologically.
 Immunohistochemistry 
 Paraffin-embedded samples were prepared as reported previ-
ously  [13] . For immunohistochemistry (IHC) against filaggrin, 
a mouse anti-human monoclonal antibody (IgG1 kappa, clone 
15C10; Vector Laboratories, Burlingame, Calif., USA), a bioti-
nylated secondary goat anti-mouse antibody (LSAB kit; Dako, 
Carpinteria, Calif., USA), streptavidin conjugated with horse-
radish peroxidase, and the substrate 3-amino-9-ethyl carbazole 
were used. Sections were also counterstained with Mayer’s hae-
matoxylin before analysis by light microscopy. Skin biopsies 
(n = 3) from patients without AD and normal postmortem cor-
neoscleral specimens (n = 6) served as control samples. TrueBlue 
peroxidase substrate (KPL, Gaithersburg, Md., USA) was used in 
combination with mouse anti-human monoclonal anti-filaggrin 
antibodies (BioLogo, Kronshagen, Germany) to confirm the IHC 
results.
 Molecular Genetic Analysis 
 DNA samples obtained from paraffin-embedded specimens 
were genotyped twice for R501X and 2282del4 using two different 
methods: the iPLEX TM method (Sequenom, San Diego, Calif., 
USA) by means of matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry and the TaqMan allelic discrim-
ination method (Applied Biosystems, Foster City, Calif., USA), as 





Fig. 1. Filaggrin expression in normal skin and corneal samples. 
Filaggrin expression in the skin ( a ), a normal conjunctival and a 
normal corneal specimen ( b ,  c ) were detected by IHC. In skin spec-
imens, the staining for filaggrin was detected in the SC and hair 
follicle (arrows;  a , ×40). In ocular specimens, filaggrin was detect-
ed in the conjunctiva ( b , ×40;  c , ×100) and in the corneal epithe-
lium ( d , ×200;  e , ×400). Higher resolution ( e ) of the corneal epi-
thelium shows that filaggrin expression is more pronounced but 
not restricted to the nuclei of the basal cell layer. Filaggrin IHC was 
also performed in atopic ( f , ×100) and non-atopic ( g , ×100) kera-
titis samples. The stroma in a keratitis sample ( f ) shows an infiltra-
tion of chronic inflammatory cells; an additional retrocorneal 
membrane (arrowheads) can be detected. In the case of acute ker-
atitis due to a Pseudomonas infection ( g ) in a patient without AD, 
a massive acute stromal inflammatory infiltration can be discov-
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 As expected, the skin tissue displayed filaggrin expres-
sion in the SC ( fig. 1 a), whereas in the normal cornea, 
filaggrin expression was observed in the basal epithelial 
layer ( fig. 1 b–e) with rather pronounced nuclear staining 
( fig. 1 e). In contrast, all other corneal specimens from 
AD patients did not display filaggrin staining ( table 1 ; 
 fig. 1 f). Interestingly, the control specimens from kerati-
tis patients without AD were also negative for filaggrin 
( fig. 1 g).
 Molecular Genetic Analysis 
 Genotyping of the  FLG mutations R501X and 2282del4 
revealed wild-type alleles in all samples from AD patients 
and in all non-atopic patients with keratitis.
 Discussion 
 Filaggrin is a key epidermal protein important for the 
maintenance of skin barrier function. Interestingly, filag-
grin is not only expressed in the skin but also in the cor-
neal epithelium, but much less is known about its role 
here. As previously reported  [15] , we could confirm a pos-
itive expression of filaggrin in normal corneal epithelium, 
as well as in the SC of skin samples. Filaggrin was mainly 
expressed in the basal layers of corneal epithelium ( fig. 1 b–
e) whereas it is expressed in the superficial layers of the 
epidermis ( fig. 1 a). This might already indicate a different 
function for filaggrin in the corneal epithelium than in the 
SC of the skin. Tong et al.  [15] assumed that filaggrin plays 
a role in compensating ocular surface stress.
 Since a common aetiology for ichthyosis vulgaris, AD 
and keratoconus is assumed, and filaggrin expression is 
altered in those diseases, we investigated its corneal ex-
pression in patients with AD and corneal diseases. We 
included a second group of corneal specimens from kera-
titis patients but without any clinical history of atopic dis-
eases. None of the AD corneal or non-atopic keratitis 
samples showed any filaggrin expression. Therefore, we 
conclude that the lack of filaggrin expression in the ocular 
surface specimens from AD patients is most likely sec-
ondary, e.g. due to inflammation, no matter whether the 
inflammation is related to AD or a different aetiology. 
This assumption is supported by the fact that none of the 
AD patients were carriers of the common  FLG mutations 
(R501X and 2282del4). Similar observations were also 
 reported for clinically affected skin specimens from AD 
patients without any of the known  FLG mutations. These 
samples revealed a reduced or even missing filaggrin ex-
pression, which was suggested to be related to inflamma-
tory processes  [16] . The reason for the absent filaggrin 
expression is yet unclear. Potential explanations include 
(1) a reduced expression related to a (low-grade) inflam-
matory status in cases of keratitis, or (2) an enhanced pro-
teolytic processing of filaggrin by up-regulated or acti-
vated proteases/caspases that degrade filaggrin. Activa-
tion of proteolytic enzymes such as kallikreins, e.g. 
KLK-5 or KLK-7, or caspases, e.g. caspase-14  [1] , could 
be induced by inflammation. Furthermore, other rare 
 FLG mutations might lead to a reduced expression of fil-
aggrin, which may have been missed. However, this seems 
unlikely since the analysed mutations account for 80% of 
the total risk alleles  [2–6] .
 In conclusion, corneal specimens from all analysed 
AD patients showed a lack of filaggrin expression inde-
pendently of the two most common  FLG mutations 
(R501X and 2282del4). The reduced filaggrin expression 
in the corneal epithelium was most likely a consequence 
of an ongoing inflammatory process, since non-atopic in-
flammatory corneal disorders displayed the same pheno-
type.
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